Claims for Patent: 8,142,991

Summary for Patent: 8,142,991

Title:	Cyclic implant perfusion, cleaning and passivation process and implant produced thereby
Abstract:	This invention is a novel method for perfusion of a porous implant which achieves efficient interpenetration of desired factors into and removal of undesirable factors from the pores of the implant, cleaning of the implant, efficient passivation of the implant (inactivation of pathogens, microorganisms, cells, viruses and the like and reduction in antigenicity thereof), and the novel implant produced by such treatment. The process presents a system wherein the rate of pressure cycling, the fact of pressure cycling, and the amplitude of pressure cycling, results in highly cleaned tissues and other implants for implantation. Target decontamination goals for this process include between about a one (1) to twelve (12) log reduction in bacterial contamination, between about a one (1) to fifteen (15) log reduction in enveloped virus contamination, up to about a five (5) log reduction in non-enveloped virus contamination, between about a two (2) to ten (10) fold reduction in endotoxin, maintenance of implant or graft biologic and biomechanical properties, absence of tissue toxicity due to cleaning solutions used, and reduced implant antigenicity.
Inventor(s):	Mills; C. Randal (Alachua, FL), Wironen; John F. (Gainesville, FL), Hanstke; Sean (Woodbridge, CA)
Assignee:	RTI Biologics, Inc. (Alachua, FL)
Application Number:	12/389,124
Patent Claims:	1. A method for cleaning allograft tissue comprising in any order: i. exposing allograft tissue to a cleaning solution at a pressure greater than atmospheric pressure; ii. exposing said allograft tissue to a cleaning solution at a pressure less than atmospheric pressure; and iii. cycling between step (i) and (ii) sufficient times to produce a cleaned allograft tissue; wherein said allograft tissue is submerged in said cleaning solution in a pressurized chamber during at least one of steps i, ii, or iii. 2. The method of claim 1 wherein step (iii) is carried out sufficient times to produce cleaned allograft tissue that is passivated. 3. The method of claim 2 wherein the allograft tissue produced is suitable for implantation or processing for implantation in humans. 4. The method of claim 1 wherein said method occurs, at least in part, with concurrent exposure of said allograft tissue to sonication. 5. The method of claim 1 wherein said cleaning solution is selected from the group consisting of sterile water, Triton X-100, tri(n-butyl)phosphate (TNBP), 3% hydrogen peroxide, a water miscible alcohol, saline solution, povidone iodine, ascorbic acid solution, aromatic hydrocarbons, aliphatic hydrocarbons, ethers, ketone, amines, urea, guanidine hydrochloride, esters, glycoproteins, proteins, saccharides, enzymes, gaseous acids, gaseous peroxides, and mixtures thereof. 6. The method of claim 1 wherein said cleaning solution is selected from the group consisting of 6% hydrogen peroxide, 1% sodium hypochlorite, 6M urea, 4M guanidine hydrochloride, 1 N sodium hydroxide, isopropanol, sterile water, saline and mixtures thereof. 7. The method of claim 1 wherein said allograft tissue comprises at least one of the following: cortical bone, cancellous bone, fascia, whole joints, tendons, ligaments, dura, pericardia, heart valves, veins, neural tissue, submucosal tissue, or cartilage, or combinations thereof. 8. The method of claim 7 wherein said allograft tissue comprises at least one of the following: cortical bone or cancellous bone, or combinations thereof. 9. The method of claim 7 wherein said allograft tissue comprises at least one of the following: fascia, whole joints, tendons, ligaments, dura, pericardia, heart valves, veins, neural tissue, submucosal tissue, or cartilage, or combinations thereof. 10. The method of claim 1 wherein said allograft tissue is derived from a single donor. 11. The method of claim 1 wherein said allograft tissue is derived from a pool of donor tissues. 12. The method of claim 1, further comprising placing said cleaned allograft tissue into a sterile, sealable package. 13. The method of claim 12, further comprising performing a surface decontamination step prior to or after sealing said package. 14. The method of claim 1 wherein the allograft tissue is perfused or coated with a bioactive substance. 15. The method of claim 14 wherein said bioactive substance is a drug or a growth factor. 16. The method of claim 15 wherein said growth factor is selected from the group consisting of a bone morphogenetic protein, tissue growth factor beta or a member of the tissue growth factor beta family of growth factors, cartilage-derived morphogenetic proteins I or II or both, a cartilage derived growth factor, an angiogenic factor, and platelet derived growth factor. 17. The method of claim 1 wherein pressures less than atmospheric pressure down to 60 torr are employed. 18. The method of claim 17 wherein the pressures less than atmospheric pressure are between about 60 to 100 torr. 19. The method of claim 1 wherein pressures greater than atmospheric pressure up to 10 atmospheres are employed. 20. The method of claim 19 wherein the pressures greater than atmospheric pressure are between about 6 to 10 atmospheres. 21. The method of claim 1, further comprising the step of: iv. machining said allograft tissue to final dimensions. 22. The method of claim 21, further comprising the step of: v. conducting steps (i)-(iii) using the same or different cleaning solutions. 23. The method of claim 21, further comprising placing said cleaned allograft tissue into a sterile, sealable package. 24. The method of claim 23, further comprising performing a surface decontamination step prior to or after sealing said package. 25. The method of claim 1 wherein any or all steps are conducted at a temperature between about 37 degrees centigrade and about 80 degrees centigrade. 26. The method of claim 25 wherein any or all steps are conducted at about 50-60 degrees centigrade. 27. A method for making an implant which comprises combining allograft tissue to form a composite implant wherein said allograft tissue is treated according to the method of claim 1.

Details for Patent 8,142,991

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2018-11-13